Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18th 2019

Lenvatinib in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate.

Dr. Moore on the Impact of the SOLO-1 Trial in Ovarian Cancer

March 18th 2019

Kathleen N. Moore, MD, associate director for clinical research, gynecologic oncologist at The Stephenson Cancer Center, The University of Oklahoma, explores the impact of the SOLO-1 trial in the field of ovarian cancer, in particular, the benefits olaparib provides and the light it shines on the importance of using genetic testing to inform treatment decisions.

Individualized Dosing Reduces Niraparib-Related TEAEs in Ovarian Cancer Maintenance

March 17th 2019

Adverse events decreased among patients with high-risk ovarian cancer who received a 200- or 300-mg individualized starting dose of niraparib, based upon baseline bodyweight and platelet count, compared with a 300-mg fixed starting dose.

Repeat Use of PARP Inhibitors Could Be Effective Strategy in Ovarian Cancer

March 17th 2019

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, suggesting that repeat use could become more common.

Dr. Coleman on the Effect of Age on Rucaparib Efficacy in Ovarian Cancer

March 17th 2019

Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the effect of age on the efficacy of rucaparib (Rubraca) in patients with recurrent ovarian carcinoma.

Maintenance Niraparib Extends PFS Without Symptoms, Toxicities in Recurrent Ovarian Cancer

March 17th 2019

Patients with recurrent ovarian cancer who received niraparib maintenance therapy experienced more progression-free time without experiencing symptoms or toxicity compared with placebo; the benefit was 4-fold for those with germline (g) BRCA-mutated disease and 2-fold for non-gBRCA-mutated ovarian cancer.

Dr. Konstantinopoulos on Immunotherapy in Ovarian Cancer

March 8th 2019

Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.

New Strategies and Novel Agents Transform Ovarian Cancer Into a Chronic Condition

March 7th 2019

The immediate future of clinical investigation in ovarian cancer is remarkably exciting, with a number of novel agents and combination strategies currently being examined in multiple clinical trials.

Dr. Campos Discusses Differences Between PARP Inhibitors in Recurrent Ovarian Cancer

March 5th 2019

Susana Campos, MD, MPH, assistant professor of medicine, Harvard Medical School, and Dana-Farber Cancer Institute, discusses differences between PARP inhibitors in recurrent ovarian cancer.

Mirvetuximab Soravtansine Misses Primary Endpoint in Ovarian Cancer Trial

March 1st 2019

Mirvetuximab soravtansine did not improve progression-free survival compared with chemotherapy in patients with folate receptor alpha–positive, platinum-resistant ovarian cancer and in an overall patient population, missing the primary endpoint of the phase III FORWARD I trial.

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer

March 1st 2019

The role of intraperitoneal chemotherapy in epithelial ovarian cancer has been a controversial subject for almost 3 decades; now, investigators are moving away from its use.

Dr. Grisham on MEK Inhibition in Low-Grade Serous Ovarian Cancer

February 27th 2019

Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses MEK inhibition in the treatment of patients with low-grade serous ovarian cancer.

Dr. Landen on Molecular Subtypes of Ovarian Cancer

February 23rd 2019

Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the molecular subtypes of ovarian cancer.

Dr. Eskander on Need for Biomarkers in Ovarian Cancer

February 21st 2019

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses the need for more effective biomarkers in the treatment of patients with ovarian cancer.

New Agents Push the Envelope in Ovarian Cancer

February 10th 2019

Although there have been numerous studies evaluating the role of different therapy schedules, cytotoxic agents, and routes of administration in ovarian cancer, the backbone of therapy remains a combination of a platinum and a taxane.

Dr. Karam on the Use of Laparoscopy in Advanced Ovarian Cancer

February 9th 2019

Amer Karam, MD, associate clinical professor of Gynecologic Oncology at Stanford Hospital and director of Robotic Surgery and Outreach in the Division of Gynecologic Oncology at Stanford Medicine, discusses the use of laparoscopy in advanced ovarian cancer.

Dr. Grisham on Frontline Treatment for Low-Grade Serous Ovarian Cancer

February 5th 2019

Rachel N. Grisham, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses frontline treatment options for patients with low-grade serous ovarian cancer.

Dr. Eskander on Combination Approaches With Immunotherapy in Ovarian Cancer

February 1st 2019

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses combination approaches with immunotherapy in ovarian cancer.

Expert Focuses on Facets of Genetic Testing in Ovarian Cancer

January 31st 2019

Huma Q. Rana, MD, discusses the evolution of genetic testing in ovarian cancer and the genes that are associated with an increased risk of subsequent cancer development.

Studies Seek to Expand on PARP Inhibitor Success in Ovarian Cancer

January 29th 2019

Susana Campos, MD, MPH, highlights the success with PARP inhibitors in the relapsed and maintenance ovarian cancer settings.